SML4054
AFQ056
≥98% (HPLC)
Synonym(s):
(3aR,4S,7aR)-Octahydro-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methyl ester, AFQ 056, Mavoglurant
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C19H23NO3
CAS Number:
Molecular Weight:
313.39
UNSPSC Code:
12352200
MDL number:
NACRES:
NA.21
InChI key
ZFPZEYHRWGMJCV-ZHALLVOQSA-N
SMILES string
O[C@]1(C#CC2=CC(C)=CC=C2)[C@@]3([H])[C@@](N(C(OC)=O)CC3)([H])CCC1
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Orally active, potent and selective mGluR5 antagonist.
AFQ056 (Mavoglurant) is an orally active, potent and selective antagonist of metabotropic glutamate receptor 5 (mGluR5). AFQ056 was investigated for treatment of fragile X syndrome and for Parkinson′s disease.
AFQ056 (Mavoglurant) is an orally active, potent and selective antagonist of metabotropic glutamate receptor 5 (mGluR5). AFQ056 was investigated for treatment of fragile X syndrome and for Parkinson′s disease.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kirstie A Bennett et al.
The Journal of pharmacology and experimental therapeutics, 377(1), 157-168 (2021-02-06)
The metabotropic glutamate receptor 5 (mGlu5) is a recognized central nervous system therapeutic target for which several negative allosteric modulator (NAM) drug candidates have or are continuing to be investigated for various disease indications in clinical development. Direct measurement of
Sébastien Jacquemont et al.
Science translational medicine, 3(64), 64ra1-64ra1 (2011-01-07)
Fragile X syndrome (FXS) is an X-linked condition associated with intellectual disability and behavioral problems. It is caused by expansion of a CGG repeat in the 5' untranslated region of the fragile X mental retardation 1 (FMR1) gene. This mutation
Laurent Grégoire et al.
Parkinsonism & related disorders, 17(4), 270-276 (2011-02-15)
Overactivity of glutamatergic transmission has been implicated in Parkinson's disease (PD) and levodopa (L-Dopa)-induced dyskinesias. Striatal metabotropic glutamate receptors type 5 (mGluR5) are abundant and provide specific targets to modulate glutamatergic activity. This study investigated the acute effects of the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service